CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.65
+1.37%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-24.0%
Return on equity
-22.6%
Return on assets
-25.2%
Return on invested capital
0.00x
Asset turnover
-$44.5M
Cash from operations
$2.56
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026